Literature DB >> 15868907

Thrombospondin-1 (TSP-1) and TSP-1-derived heparin-binding peptides induce promyelocytic leukemia cell differentiation and apoptosis.

Arlette Bruel1, Myriem Touhami-Carrier, Annick Thomaidis, Chantal Legrand.   

Abstract

Thrombospondin-1 (TSP-1) is a multifunctional adhesive glycoprotein that is synthesized by several cell types and modulates cell growth and differentiation. In this study, we showed that the amount of TSP-1 secreted by two human leukemia cell lines, HL-60 and NB4, increased markedly during differentiation of these cells by all-trans retinoic acid (ATRA) (10(-7) M), reaching about 100 ng/10(6) cells after 3 days. Addition of purified TSP-1 alone (10(-9)-5 x 10(-8) M) to HL-60 or NB4 cell cultures dose-dependently inhibited cell growth and differentiation. Differently to ATRA, TSP-1-induced differentiation of HL-60 and NB4 cells occurred independently of Bcl-2 regulation, as shown by immunofluorescence and Western immunoblotting. At day 5, TSP-1 also induced promyelocytic leukemia cell apoptosis. The percentage of apoptotic cells in NB4 cultures was higher with TSP-1 (5 x 10(-8) M) than with ATRA (10(-7) M) (46+/-3% versus 19+/-7%, p<0.001), whereas similar levels of apoptosis (37+/-7% and 38+/-6%) were reached with both agents in HL-60 cultures. Studies performed with synthetic peptides derived from the TSP-1 sequence indicated that two heparin-binding peptides, Hep-I and GGWSHW, located within the NH2-terminal and type 1 repeats respectively, were strong inducers of apoptosis of HL-60 and NB4 cells, suggesting that cell surface heparan sulfate molecules might be involved in the apoptotic effect of TSP-1 on promyelocytic cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868907

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

Review 1.  Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.

Authors:  Y Mirochnik; A Kwiatek; O V Volpert
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

2.  Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to anoikis.

Authors:  Manuel A Pallero; Carrie A Elzie; Jiping Chen; Deane F Mosher; Joanne E Murphy-Ullrich
Journal:  FASEB J       Date:  2008-07-24       Impact factor: 5.191

Review 3.  Role of cell cycle regulatory molecules in retinoic acid- and vitamin D3-induced differentiation of acute myeloid leukaemia cells.

Authors:  X T Hu; K S Zuckerman
Journal:  Cell Prolif       Date:  2014-03-19       Impact factor: 6.831

Review 4.  Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.

Authors:  Yasuyoshi Miyata; Hideki Sakai
Journal:  Int J Mol Sci       Date:  2013-06-07       Impact factor: 5.923

5.  E2F-1 directly regulates thrombospondin 1 expression.

Authors:  Wei Ji; Wei Zhang; Wuhan Xiao
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

Review 6.  Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.

Authors:  Marco Rusnati; Chiara Urbinati; Silvia Bonifacio; Marco Presta; Giulia Taraboletti
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-23

Review 7.  Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.

Authors:  Chen Zhao; Jeffrey S Isenberg; Aleksander S Popel
Journal:  J Cell Mol Med       Date:  2018-02-14       Impact factor: 5.310

Review 8.  Protein C-Mannosylation and C-Mannosyl Tryptophan in Chemical Biology and Medicine.

Authors:  Shiho Minakata; Shino Manabe; Yoko Inai; Midori Ikezaki; Kazuchika Nishitsuji; Yukishige Ito; Yoshito Ihara
Journal:  Molecules       Date:  2021-08-30       Impact factor: 4.411

9.  A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA.

Authors:  Morgane Gourvest; Etienne De Clara; Hsin-Chieh Wu; Christian Touriol; Fabienne Meggetto; Hugues De Thé; Stéphane Pyronnet; Pierre Brousset; Marina Bousquet
Journal:  Leukemia       Date:  2021-06-15       Impact factor: 11.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.